For Curran Simpson, Chief Operations and Technology Officer at REGENXBIO, Maryland has the “ideal mix” of talent for process development and manufacturing. Because if that, it was a no-brainer for the company to opening of its new Manufacturing Innovation Center gene therapy manufacturing facility in Rockville.
The new 132,000 square-foot-facility was designed to boost manufacturing of the company’s NAV Technology-based adeno-associated virus (AAV) vectors at scales up to 2,000 liters. REGENXBIO’s AAV vector platform has been licensed to other companies and was used in the development of Novartis’ Zolgensma, a gene therapy for spinal muscular atrophy. With its new site that includes two independent bulk drug substance production suites, a final drug product suite and integrated quality control labs, REGENXBIO is one of only a few gene therapy companies worldwide with a GMP facility capable of production at scales up to 2,000 liters.
Read the full article via the Maryland Tech Council’s “It’s Better Here” newsletter at: myemail.constantcontact.com
